Canada Pension Plan Investment Board I Mab Transaction History

Canada Pension Plan Investment Board

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.21 - $1.9 $323,745 - $508,360	267,558 Added 581.12%	313,600 $595,000
Q3 2023 Nov 09, 2023	BUY	$1.18 - $3.06 $54,329 - $140,888	46,042 New	46,042 $60,000
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $356,489 - $1.1 Million	88,900 Added 10.6%	927,400 $3.72 Million
Q2 2022 Aug 12, 2022	BUY	$8.27 - $18.43 $1.83 Million - $4.08 Million	221,500 Added 35.9%	838,500 $9.48 Million
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $1.83 Million - $6.85 Million	146,000 Added 31.0%	617,000 $10 Million
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $13.7 Million - $22.6 Million	303,000 Added 180.36%	471,000 $22.3 Million
Q3 2021 Nov 15, 2021	SELL	$57.18 - $84.43 $11.6 Million - $17.2 Million	-203,300 Reduced 54.75%	168,000 $12.2 Million
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $17.8 Million - $31.2 Million	371,300 New	371,300 $31.2 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $74.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Canada Pension Plan Investment Board, based on Form 13F filings with the SEC.

Stay updated on Canada Pension Plan Investment Board with notifications on news.